Beta Bionics, Inc. (BBNX) Stock Statistics & Valuation Metrics

Beta Bionics, Inc. has a market cap or net worth of $461.13M. The enterprise value is $436.76M.

Beta Bionics, Inc. has 44,382,145 shares outstanding. The number of shares has decreased by -2.65% in one year.

Beta Bionics, Inc.’s return on equity (ROE) is -0.25 and return on invested capital (ROIC) is -23.91%.

The current PE Ratio of Beta Bionics, Inc. is ―. Beta Bionics, Inc.’s PEG ratio is 0.21.

In the last 12 months, Beta Bionics, Inc. had revenue of 100.25M and earned -73.20M in profits. Earnings per share was -1.81.

In the last 12 months, operating cash flow was -42.30M and capital expenditures -3.39M, giving a free cash flow of -45.69M billion.

Beta Bionics, Inc. pays an annual dividend of ―, resulting in a dividend yield of ―

Beta Bionics, Inc. upcoming earnings date is May 12, 2026, After Close (Confirmed).

Beta Bionics, Inc. as a current ratio of 8.66, with Debt / Equity ratio of 2.54%

In the past 12 months, Beta Bionics, Inc. has paid 1.00K in taxes.

Beta Bionics, Inc. EV to EBITDA ratio is -16.61, with an EV/FCF ratio of 0.00.

Beta Bionics, Inc. has $219.22M in cash and marketable securities with $7.30M in debt, giving a net cash position of $211.92M billion.

Gross margin is 55.40%, with operating margin of -71.50%, and net profit margin of -73.02%.

The average price target for Beta Bionics, Inc. is $22.89, which is 11.43% higher than the current price. The consensus rating is Moderate Buy